Organ transport device maker TransMedics prices upsized IPO at $16 midpoint
TransMedics Group, a medical device company that provides a system for donor organ transport, raised $91 million by offering 5.7 million shares at $16, the midpoint of the $15 to $17 range. The company had originally filed to offer 4.7 million shares at the same range of $15-$17.
TransMedics Group plans to list on the Nasdaq under the symbol TMDX. Morgan Stanley and J.P. Morgan acted as lead managers on the deal.
The article Organ transport device maker TransMedics prices upsized IPO at $16 midpoint originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Latest IPOs Videos
- US IPO Week Ahead: A biotech and a Chinese hologram company take on a tough IPO market
- Zentalis Pharmaceuticals prices upsized IPO at $18, the high end of the range
- Chinese augmented reality platform WiMi Hologram prices US IPO at $5.50 low end
- Nasdaq’s Head of Healthcare Listings on the State of IPOs During the Coronavirus Pandemic